Michigan Seeks Input Into Adult-use Marijuana Rulemaking

Michigan regulators are asking for volunteers to provide input for the state’s new recreational marijuana industry rules, and the cannabis industry is responding to ensure its views are heard.

The state is forming work groups to cover four regulatory topics:

Existing medical marijuana license holders interested in entering the adult-use market.
Municipalities that are considering allowing licensed recreational facilities in their community.
Attorneys who represent marijuana establishments that have an interest in the adult-use market.
Individuals or businesses interested in participating in the market as potential licensees or consumers.

Morgan Fox, spokesman for the National Cannabis Industry Association (NCIA), noted that its Michigan members will be actively involved in the effort, as will its allied association, the Michigan Cannabis Industry Association.

Fox said the NCIA also is planning to make its resources, such as best practices and industry standards, available to regulators.

Josh Hovey, spokesman for the Michigan Cannabis Industry Association, confirmed to Marijuana Business Daily that the group “has members at every licensing level that have applied to lend their input to the state’s rulemaking process.”

Matt Schweich, deputy director of the Marijuana Policy Project, said MPP does not plan to be heavily involved in the rulemaking process but will closely monitor developments.

Details on how to volunteer are available in this news release.

Selections will be announced by March 11, and work groups are set to start meeting by the end of March.

The state has said it will start taking business license applications by Dec. 6, with the commercial market expected to launch sometime in 2020.

Jeff Smith can be reached at [email protected]

Original Article Source: https://mjbizdaily.com/michigan-seeks-input-into-adult-use-marijuana-rulemaking/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned. When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...

Norma Pence

Search This Blog